ABSTRACf. Serious suggestions have been made that dietary supplementation with folic acid (FA) and perhaps other vitamins during pregnancy may reduce the incidence of neural tube defect (NTD) in human newborns. The purpose of these experiments was to evaluate the effect of continuous infusion of FA on the incidence of NTDs induced by arsenate. This teratogen induces NTDs in up to 90% of golden hamster fetuses when administered acutely during critical stages of embryogenesis. FA was administered by subcutaneously implanted osmotic minipumps beginning on the 6th day of gestation, 48 h before an acutely administered dose of sodium arsenate. The protective effect of FA was examined at three teratogenic dose levels of arsenate: optimal, with 90% NTDs, intermediate, with 38% NTDs, and low, with 20% NTDs. Fetuses were recovered at day 13 of gestation and examined for NTDs and other malformations. Maternal red cell folate levels were determined on day 8, 48 h after implantation of the pumps. The results show that the maternal red blood cell level of FA can be significantly increased within 48 h by chronic infusion to levels which are almost two times (550 ng/ml) control levels. There was no significant protection against arsenate-induced NTDs following FA supplementation at any of three levels of this teratogen. (Pediatr Res 20:761-762,1986) Abbreviations FA, folic acid NTD, neural tube defect OMP, osmotic minipump further evidence that FA supplementation during pregnancy does not reduce the incidence of NTDs produced by a potent central nervous system teratogen. Specifically, we show in the hamster model that the incidence of NTDs produced by acute exposure to arsenate is not reduced by continuous dosing with FA prior or during the critical stages of embryogenesis.
ABSTRACf. Serious suggestions have been made that dietary supplementation with folic acid (FA) and perhaps other vitamins during pregnancy may reduce the incidence of neural tube defect (NTD) in human newborns. The purpose of these experiments was to evaluate the effect of continuous infusion of FA on the incidence of NTDs induced by arsenate. This teratogen induces NTDs in up to 90% of golden hamster fetuses when administered acutely during critical stages of embryogenesis. FA was administered by subcutaneously implanted osmotic minipumps beginning on the 6th day of gestation, 48 h before an acutely administered dose of sodium arsenate. The protective effect of FA was examined at three teratogenic dose levels of arsenate: optimal, with 90% NTDs, intermediate, with 38% NTDs, and low, with 20% NTDs. Fetuses were recovered at day 13 of gestation and examined for NTDs and other malformations. Maternal red cell folate levels were determined on day 8, 48 h after implantation of the pumps. The results show that the maternal red blood cell level of FA can be significantly increased within 48 h by chronic infusion to levels which are almost two times (550 ng/ml) control levels. There was no significant protection against arsenate-induced NTDs following FA supplementation at any of three levels of this teratogen. (Table 1) . A second group of animals was implanted with two OMP on the 6th day of gestation, charged with FA (Folvite) at a concentration of 5 mg/ml, in a manner described previously (2) . Forty-eight hours later, on day 8 of gestation, they received the same dosage regimens of sodium arsenate as the animals in the first group. The presence in the mothers of one or two saline pumps or pumps containing FA alone has no teratogenic effect in the golden hamster (4). The animals were killed by CO 2 inhalation on day 13 and examined for NTDs in a manner described previously (4) Embryonic resorption sites were also recorded.
A third group of animals was implanted with two pumps each filled with FA on day 6 ofgestation. These animals were sacrificed on day 8 of gestation and cardiac blood obtained for folate assays. Blood samples were collected in glass tubes with EDTA as anticoagulant and frozen immediately after the hematocrit was determined. The red cell folate levels in these blood samples were then determined by radioimmunoassay using the Coming Folate Radioassay Kit. The same assay technique had been used previously for saline-filled pumps and single pumps filled with folate (2).
RESULTS
The data on the effect offolic acid supplementation of arsenicinduced malformations are summarized in Table 1 . The frequency of neural tube defects in litters from dams receiving arsenic alone was compared to that from dams receiving the same dose of arsenic along with FA. The statistical significance of the difference between these two groups was estimated by using the unpaired t test on the Freeman-Tukey arcsin transformations of the proportion of fetuses affected per litter. The statistical sample size is thus the number of litters per group.
Hamsters maintained in this laboratory on regular lab food have unsupplemented maternal red cell folate levels ranging from 272-345 ng/ml (mean = 301) on the 8th day of gestation (2) . In that study, a single pump containing folic acid (Folvite) increased the maternal red cell level of folate in hamster blood to a range of 336-560 ng/ml with a mean level of 408 over a 48-h period Deficiencies of certain vitamins, including FA, have been implicated in the development of NTDs in human pregnancies (1). Clinical trials, using FA and vitamin supplementation as a means of reducing the incidence ofNTDs in human pregnancies, are now underway. We have reported that implantation of aMP (Alzet, model 2001) containing FA (Folvite, Lederle Co.) does not prevent the NTDs induced either by maternal hyperthermia or alcohol ingestion in the hamster embryo (2). Trotz et al. (3) have reported preliminary data suggesting that folinic acid supplementation by the osmotic minipump in the mouse decreased exencephaly caused by valproic acid (3 Table 2 . Maternal red cell folate levels (ng/ml) on day 8 of gestation in hamster of exposure. In current experiments, with two pumps containing Folvite in place for the same amount oftime, the mean maternal red cell folate level for six animals was 527 ng/ml with a range of 467-592 (Table 2 ). This level was maintained throughout the 24-h period of critical embryogenesis, and beyond, as demonstrated by our previous work (2) .
teratogenic level (6.0 micromolar arsenic) in about 5 h (8). As shown in Table 1 , even the effects of low-level teratogenic doses of arsenate are not mitigated by the presence of FA at levels which are above those in FA-supplemented human pregnancies (9) .
While the primary etiologies of NTDs may be complex, there must be a final common morphogenetic pathway for these lesions, whatever their causes. NTDs produced by arsenate are morphologically identical to those NTDs caused by many other experimental agents, as well as those occurring spontaneously.
Continuous FA supplementation alone during the critical stages of embryogenesis does not reduce the incidence of NTDs associated with a potent NTD-inducer such as arsenate in this animal model system. The use of FA and/or multivitamin supplementation as a means of reducing human NTDs is currently receiving considerable attention and study (6) . The use ofOMPs as a method of delivery of FA assures the constancy of blood levels of this compound and precludes any problems associated with gastrointestinal absorption or variation in feeding habits.
In our experience with more than 15,000 litters of this species, the incidence ofspontaneously occurring NTDs is less than 0.1 %. Day 8 of gestation in this species has been shown to be the most sensitive period for the induction of NTDs by arsenate (6) . Arsenate, in the hamster model, is a very potent and consistent inducer of NTDs (6) . It is important to note that the 8th day of gestation in the hamster corresponds to the 17-to 28-day period in human embryonic development (7) . The neural tube in the hamster develops, folds, and closes completely in the 24-h period between days 8 and 9 of gestation. We have determined that following an acute bolus intraperitoneal injection of 64.2 /LIDOI/ kg of sodium arsenate, the maternal blood reaches a level of 220 micromolar arsenic within 30 min and falls to a minimally
